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Context: There is an ongoing debate on the optimal management of patent ductus
arteriosus (PDA) in preterm infants. Identifying subgroup of infants who would benefit
from pharmacological treatment might help.
Objective: To investigate the modulating effect of the differences in methodological
quality, the rate of open-label treatment, and patient characteristics on relevant outcome
measures in randomized controlled trials (RCTs).
Data Sources: Electronic database search between 1950 and May 2020.
Study Selection: RCTs that assessed pharmacological treatment compared to
placebo/no treatment.
Data Extraction: Data is extracted following the PRISMA guidelines. Outcome
measures were failure to ductal closure, surgical ligation, incidence of necrotizing
enterocolitis, bronchopulmonary dysplasia, sepsis, periventricular leukomalacia,
intraventricular hemorrhage (IVH) grade ≥3, retinopathy of prematurity and mortality.
Results: Forty-seven studies were eligible. The incidence of IVH grade ≥3 was lower in
the treated infants compared to the placebo/no treatment (RR 0.77, 95% CI 0.64–0.94)
and in the subgroups of infants with either a gestational age <28 weeks (RR 0.77, 95%
CI 0.61–0.98), a birth weight <1,000 g (RR 0.77, 95% CI 0.61–0.97), or if untargeted
treatment with indomethacin was started <24 h after birth (RR 0.70, 95% CI 0.54–0.90).
Limitations: Statistical heterogeneity caused by missing data and variable definitions
of outcome parameters.
Conclusions: Although the quality of evidence is low, this meta-analysis suggests that
pharmacological treatment of PDA reduces severe IVH in extremely preterm, extremely
low birth weight infants or if treatment with indomethacin was started <24 h after birth.
No other beneficial effects of pharmacological treatment were found.
Keywords: ductus botalli, patent ductus arteriosis, premature (babies), ibuprofen, indometacin, acetaminophen
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INTRODUCTION
Patent ductus arteriosus (PDA) is common in preterm and
very low birth weight infants (1). Persistence is associated with
a higher risk of morbidities, including bronchopulmonary
dysplasia (BPD), necrotizing enterocolitis (NEC), and
intraventricular hemorrhage (IVH), and mortality (2).
Nevertheless, pharmacological treatment or surgical closure
of PDA is not without adverse effects (3, 4). After many decades
of clinical research, the question remains open if, when, and
how PDA should be treated in preterm infants (5). Globally,
there has been a shift from early pharmacological treatment
toward a more expectant management policy (6). A uniform
definition of a hemodynamic significant PDA does not exist,
nor is there clear evidence in favor of or against many of the
approaches to treating PDA (7–9). Since 1976 we know that
pharmacological treatment is an effective way of ductal closure
(10). A recent meta-analysis, however, showed that neither short-
term nor long-term outcomes seem to differ between treated
and untreated patients (11). This sparked an ongoing debate
on the optimal approach to treating PDA, which ranges from
expectant management to aggressive treatment with a variety of
cyclooxygenase inhibitors or acetaminophen with varying doses
and at different intervals (5). Although the results of randomized
controlled trails (RCTs) on PDA treatment have been reviewed
extensively, only a small number of reviews stratified the results
according to infant characteristics, methodological quality
(11, 12), timing of treatment (12), or to the definitions of a
hemodynamic significant PDA (9).
To the best of our knowledge this is the first comprehensive
systematic review of RCTs to investigate the modulating
effect of the methodological quality, the rate of open-label
treatment in the placebo/no treatment groups, and several
patient characteristics on the benefits, or adverse effects, of
pharmacological treatment of PDA in preterm infants. We aim
to identify specific subgroups of preterm infants at high risk of
adverse outcomes, who would benefit from active closure of PDA.
METHODS
Our study is performed in accordance with the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) guidelines (13).
Search Strategy
We searched the following databases: PubMed, the Ovid
Embase, and the Cochrane Library. We searched for papers
published between 1950 up to and including April 2020.
By using the Boolean operators AND and OR, we used all
possible combinations of the following search terms: infant,
newborn, neonate, preterm, premature, ductus, arteriosus,
Botalli. We also used the Mesh terms “Infant, premature,”
“Ductus Arteriosus, Patent,” and “Ductus Arteriosus” in the
PubMed database. The complete search strategy can be found in
Supplement 1. Subsequently, we assessed the publications cited
by the selected studies for relevant material eligible for possible
additional inclusion.
Study Selection
Three authors (EJ, TH, and WdB) independently screened the
publications identified in our initial search for eligibility on the
basis of their titles and abstracts. Where disagreement arose,
the full text was assessed and then discussed in order to reach
consensus. We selected studies with a RCT design and written
in either English, Dutch, or German. Generally speaking, we
included all studies that assessed pharmacological treatment
with either ibuprofen, indomethacin, or acetaminophen vs.
placebo/no treatment. We excluded animal studies, studies on
antenatal treatment, studies that included patients with a post
term age of more than 1 month, and studies concerning patients
with a congenital heart defect.
Data Extraction
Two authors (EJ and TH) performed data extraction. The
data we extracted from the selected studies were general
study parameters, demographic parameters pertaining to the
participants, treatment regime(s), and outcomes. We collected
the parameters study design, total number of patients, mean
gestational age (GA), birth weight (BW), postnatal age (PNA) at
the start of treatment, and the rate of open-label treatment in the
placebo/no treatment group. The following outcome parameters
were collected (if reported in the studies) and analyzed: mortality,
failure to close the DA, the need for surgical ligation, the
incidence of NEC (any definition), BPD (any definition),
sepsis, periventricular leukomalacia (PVL), IVH grade ≥3,
retinopathy of prematurity (ROP), oliguria, other respiratory
morbidity (e.g., pneumothorax), other gastrointestinal morbidity
[e.g., spontaneous intestinal perforation (SIP)], and long-term
neurodevelopmental impairment. In case of missing data, we
tried to contact the corresponding authors of the studies in
question and requested them to kindly provide these data.
Statistical Analysis
As ibuprofen, indomethacin, and acetaminophen are comparable
regarding their effectiveness in DA closure (11, 14), but their side
effect profiles may differ (11, 14), we performed two analyses.
In the first analysis we combined all studies reporting either
of these three drugs in comparison with placebo/no treatment.
In a second analysis we divided the studies according to which
drug was used. Subgroups were made, related to known risk
factors (GA, BW) and other factors influencing efficacy of
treatment, such as PNA. Moreover, the consequences of open
label treatment percentage in the control group were analyzed
since this is an important methodologic flaw in the RCTs. The
following strata were analyzed: BW in five subgroups: <1,000 g,
1,000–1,250 g, 1,251–1,500 g, >1,500 g, and data unknown; GA
in four subgroups: <28 weeks, 28–33 weeks, >33 weeks,
and data unknown; PNA at the start of treatment in four
subgroups: <24 h, 24–72 h, >72 h, and data unknown. Studies
with start of treatment <24 h PNA were divided into untargeted
(start treatment irrespective whether the ductus is open or
closed) and targeted (start treatment only after clinically and/or
echocardiographically confirmation of a PDA) treatment. The
rate of open-label treatment in the placebo/no treatment arm
was expressed as a percentage and divided into four groups:
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<25%, 25–50%,>50%, and data unknown. For statistical analysis
we used Review Manager (RevMan version 5.3 Copenhagen:
The Nordic Cochrane Center, The Cochrane Collaboration,
2014). The risk ratio (RR) and risk difference (RD) with a
95% confidence interval (CI) were calculated with the Mantel-
Haenszel method. We calculated the number needed to treat
(NNT) with a 95% CI for each different outcome in case of
statistical significance. We used random-effect meta-analysis if
the heterogeneity (I2) was >50% (15) and fixed-effect in case of
low heterogeneity.
Risk of Bias
We critically examined the methodological quality of the selected
studies and the risk of bias in accordance with the Cochrane
guidelines (16). The quality parameters included the type of
analysis, random sequence generation, allocation concealment,
blinding of participants and personnel, and blinding of outcome
assessment. Two authors (EJ and TH) assessed the risk of bias
assessment. When disagreement arose, a third author (WdB)
assessed the studies in order to reach consensus. The risk of
bias was calculated (low risk: 1 point, unclear risk: 2 points,
and high risk: 3 points) and the cumulative score was divided
into three subgroups: low (7–9 points in total), intermediate
(10–12 points), and high (13–21 points). We examined the
methodological quality of the studies’ outcome parameters with
the GRADE method (17). We assessed imprecision as serious
if the total number of events was <300 or if the width of the
CI of the RR was >0.25. We used the GRADE-pro GDT 2016
FIGURE 1 | PRISMA flow diagram.
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software [GRADEpro Guideline Development Tool (Software)
McMaster University, 2015] to create a “summary of findings”
table to report the quality of evidence. The GRADE approach
results in an assessment of the quality of a body of evidence in
one of four grades: high, moderate, low, or very low.
RESULTS
Study Selection
Out of the 12,139 articles we identified 10,251 as unique in our
initial search. After selection (see Figure 1) a final 47 papers were
eligible, comprising a total of 5,242 infants (18–64).
Study Characteristics and Risk of Bias
The relevant characteristics of the 47 papers are described in
Table 1 (18–64). Thirty-two (68%) of the studies analyzed the
effect of indomethacin (18–44, 46, 47, 55, 60, 61), 12 (26%)
studied the effect of ibuprofen (45, 48–54, 56–59), two (4%)
studied acetaminophen (62, 64), and one (2%) studied the
effect of either indomethacin, ibuprofen, or acetaminophen (63).
Thirteen papers (28%) included preterm infants with a mean
GA < 28 weeks (42, 44, 46–48, 50, 53, 55–58, 61, 63), and 30
(64%) included infants with a mean GA between 28 and 32 weeks
(18, 20–24, 26–30, 32–41, 43, 45, 47, 49, 51, 52, 59, 60, 62, 64).
Seventeen papers (36%) included preterm infants with a mean
BW< 1,000 g (33, 35, 39, 41–46, 48, 50, 53, 55, 56, 58, 61, 63), and
19 (40%) included infants weighing between 1,000 and 1,250 g
(20, 22–24, 27–30, 34, 36–38, 40, 47, 49, 52, 57, 62, 64). Most
studies (62%) investigated treatment that was started within 24 h’
PNA (26, 29, 30, 32, 34, 35, 37–53, 55, 58, 60–62, 64). More than
two third of the studies reported the rate of open-label treatment,
namely 25–50% in 16 (34%) (20, 22, 31, 32, 36, 37, 42, 46, 48, 50,
52, 53, 58, 60, 61, 63), and >50% in 15 (32%) studies (18, 19, 23–
25, 27, 33, 34, 40, 43, 45, 47, 51, 55, 56). The median rate of
the open-label treatment was 44.5% (range 0–85%). Twenty-one
studies (45%) were classified as having a low risk of bias (18, 21–
23, 25, 27, 29, 31, 33, 37, 38, 42, 43, 46, 47, 49, 50, 53, 56, 61, 62).
Six papers (13%) were assessed as having a high risk of bias
(19, 26, 34, 39, 40, 63).
Outcome Measures
Despite our efforts to contact the corresponding authors and
our request to provide missing data, not all data on GA, BW
and rate of open-label treatment could be retrieved. Data on
GA (19, 25, 31) and/or BW (25, 31, 60) were unavailable in
four trials (453 and 499 infants for GA and BW, respectively).
The rate of open-label treatment was unavailable for nine trials
(21, 26, 28, 30, 39, 44, 57, 59, 64).
RR of outcomes, stratified by the patient characteristics, the
quality of the studies, and the rate of open-label treatment
in the placebo/no treatment group are described in Table 2.
The meta-analyses revealed that in comparison to placebo/no
treatment, the administration of indomethacin, ibuprofen, or
acetaminophen resulted in a significantly reduced risk of failed
ductal closure (RR 0.40, 95% CI 0.33–0.48; RD −0.32, 95% CI
−0.38, −0.27; NNT 3.4, 95% CI 3.1–3.7) or risk of surgical
ligation (RR 0.61, 95% CI 0.49–0.76; RD −0.04, 95% CI −0.06,
−0.02; NNT 22.8, 95% CI 15.8–40.7), irrespective of the used
drug. This result was similar for the subcategories based on mean
BW, GA, and PNA at the start of treatment. The quality of
evidence was graded as very low or very low to low, respectively
(Supplement 2).
We found no difference for BPD, NEC, sepsis, PVL, ROP or
mortality between the intervention and control group overall,
or in any of the subgroups (Table 2), irrespective of the used
drug. In most studies BPD was defined as supplemental oxygen
requirement at 28 days’ PNA or at 36 weeks’ postmenstrual
age (PMA). Seven RCTs used radiographic criteria (19, 22, 26,
31, 33, 35, 36). Four RCTs did not state their definition of
BPD clearly (32, 43, 51, 52). Neither the overall meta-analyses
nor the subgroup analyses of the 28 days’ PNA and 36 weeks’
PMA definition of BPD revealed any differences between the
placebo/no treatment and the pharmacological treatment group.
Twenty-eight out of 47 studies started the treatment <24 h
PNA. Of these 28 studies, five started treatment only after
clinically and/or echocardiographically confirmation of a PDA
(targeted treatment) (26, 47, 51, 52, 61). All the other RCTs
started irrespective whether the ductus was open or closed within
the first 24 h after birth (untargeted treatment).
Compared to the no treatment group, the infants allocated to
the pharmacological treatment group had a lower risk of IVH
grade ≥3 (RR 0.76, 95% CI 0.62–0.93; RD −0.03, 95% CI −0.05,
−0.01; NNT 34, 95% CI 18.9–136.6). This reduced risk of IVH
grade ≥3 was also observed in the subgroups GA <28 weeks
(RR 0.77, 95% CI 0.61–0.98; RD −0.03, 95% CI −0.06, −0.00;
NNT 30.3, 95% CI 16.1–262.9), BW <1,000 g (RR 0.77, 95% CI
0.61–0.97; RD −0.03, 95% CI −0.06, −0.00; NNT 30.2, 95% CI
16.4–199.9), or if treatment was given untargeted <24 h’ PNA
(RR 0.70; 95% CI 0.57–0.87; RD −0.04, 95% CI −0.06, −0.02;
NNT 26, 95% CI 15.7–64.1).
We found a significant reduction in severe IVH only when
untargeted treatment with indomethacin was used < 24 h PNA
compared to no treatment (RR 0.70, 95% CI 0.54–0.90; RD
−0.04, 95% CI −0.07, −0.01). Forest plots for the risk of IVH
grade ≥3 are depicted for the different subgroups in Figure 2.
Furthermore, the incidence of IVH grade ≥3 in the treatment
group was significantly lower in the low and intermediate risk
of bias groups and if the rate of open-label treatment was 25–
50%. The quality of evidence was graded as very low to low
(Supplement 2).
Subgroup analyses of the other outcome measurements
proved impossible on account of the scarcity of available data.
Five RCTs described data on oliguria (37, 40–42, 62). Five studies
described the incidence of pneumothorax (30, 32, 37–39), six
studies pulmonary hemorrhage (37, 42, 46, 60, 61, 63), and one
study reported pulmonary hypertension as outcome measure
(60). Five studies described the incidence of gastrointestinal
bleeding (24, 27, 32, 40, 61), while two studies reported the
incidence of SIP (46, 61). Only three RCTs described the long-
term data on neurodevelopmental outcomes regarding motor
delay, cognitive delay, the incidence of deafness and blindness,
and neurodevelopmental impairment in general (44, 46, 64).
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TABLE 1 | Treatment, patient and, study characteristics of the RCTs included.
References Patients
(n)
Treatment characteristics Patient characteristics Study characteristics
Intervention Control Start at PNA GA (w) BW (g) Open-
label
treatment
1 2 3 4 5 6 7 Risk of bias
Nestrud et al. (18) 23 Indomethacin Placebo > 72 h 28–32 1,251–1,500 > 50% + + + ? + + ? Low
Merritt et al. (19) 24 Indomethacin No treatment 24–72 h unknown 1,251–1,500 > 50% – – – ? – + ? High
Neu et al. (20) 21 Indomethacin Placebo > 72 h 28–32 1,000–1,250 25–50% ? + + + – + ? Intermediate
Yanagi et al. (21) 17 Indomethacin Placebo > 72 h 28–32 1,251–1,500 unknown + + + ? + + ? Low
Yeh et al. (22) 55 Indomethacin Placebo > 72 h 28–32 1,000–1,250 25–50% + ? + + + + ? Low
Mahony et al. (23) 47 Indomethacin Placebo > 72 h 28–32 1,000–1,250 > 50% + + + + + + ? Low
Mullett et al. (24) 47 Indomethacin Placebo > 72 h 28–32 1,000–1,250 > 50% ? + + ? + – ? Intermediate
Gersony et al. (25) 405 Indomethacin Placebo > 72 h unknown unknown > 50% + + + ? + + ? Low
Kaapa et al. (26) 27 Indomethacin No treatment <24 h T 28–32 >1,500 unknown + ? – ? ? + ? High
Rudd et al. (27) 30 Indomethacin Placebo > 72 h 28–32 1,000–1,250 > 50% + + + + + + ? Low
Yeh et al. (28) 47 Indomethacin Placebo > 72 h 28–32 1,000–1,250 unknown + ? + ? ? + ? Intermediate
Mahony et al. (29) 104 Indomethacin Placebo < 24 h UT 28–32 1,000–1,250 < 25% + + + + ? + ? Low
Ment et al. (30) 48 Indomethacin Placebo < 24 h UT 28–32 1,000–1,250 unknown – ? + + ? + ? Intermediate
Hammerman et al. (31) 24 Indomethacin Placebo > 72 h unknown unknown 25–50% + + + + ? + ? Low
Rennie et al. (32) 50 Indomethacin Placebo < 24 h UT 28–32 1,251–1,500 25–50% ? ? + + ? ? ? Intermediate
Hammerman et al. (33) 24 Indomethacin Placebo > 72 h 28–32 <1,000 > 50% + + + + + + ? Low
Krueger et al. (34) 32 Indomethacin No treatment < 24 h UT 28–32 1,000–1,250 > 50% ? ? – ? ? + ? High
Vincer et al. (35) 30 Indomethacin Placebo < 24 h UT 28–32 <1,000 < 25% ? – + ? + + ? Intermediate
Weesner et al. (36) 26 Indomethacin Placebo 24–72 h 28–32 1,000–1,250 25–50% + ? + + ? + ? Intermediate
Bandstra et al. (37) 199 Indomethacin Placebo < 24 h UT 28–32 1,000–1,250 25–50% + + + + + + ? Low
Hanigan et al. (38) 111 Indomethacin Placebo < 24 h UT 28–32 1,000–1,250 < 25% + + + + ? + ? Low
Ment et al. (39) 36 Indomethacin Placebo < 24 h UT 28–32 <1,000 unknown – ? + + – + ? High
Lai et al. (40) 32 Indomethacin Placebo < 24 h UT 28–32 1,000–1,250 > 50% – – ? ? ? + ? High
Ment et al. (41) 431 Indomethacin Placebo < 24 h UT 28–32 <1,000 < 25% + + ? + – + ? Intermediate
Couser et al. (42) 90 Indomethacin Placebo < 24 h UT < 28 <1,000 25–50% + ? + + + + ? Low
Supapannachart et al.
(43)
30 Indomethacin Placebo < 24 h UT 28–32 <1,000 > 50% + + + ? + + ? Low
Couser et al. (44) 90 Indomethacin Placebo < 24 h UT < 28 <1,000 unknown + ? + + – + ? Intermediate
De Carolis et al. (45) 46 Ibuprofen No treatment < 24 h UT 28–32 <1,000 > 50% + – – + + + ? Intermediate
Schmidt et al. (46) 1,202 Indomethacin Placebo < 24 h UT < 28 <1,000 25–50% + + + + ? + ? Low
Osborn et al. (47) 70 Indomethacin Placebo < 24 h T < 28 1,000–1,250 > 50% ? + + + + + ? Low
Gournay et al. (48) 131 Ibuprofen Placebo < 24 h UT < 28 <1,000 25–50% + + + + – + – Intermediate
van Overmeire et al. (49) 415 Ibuprofen Placebo < 24 h UT 28–32 1,000–1,250 < 25% + + + + + + ? Low
Dani et al. (50) 155 Ibuprofen Placebo < 24 h UT < 28 <1,000 25–50% + + + + ? + ? Low
Sangtawesin et al. (51) 42 Ibuprofen Placebo < 24 h T 28–32 1,251–1,500 > 50% ? ? + + + + ? Intermediate
Sangtawesin et al. (52) 62 Ibuprofen Placebo < 24 h T 28–32 1,000–1,250 25–50% ? ? + + + + ? Intermediate
Aranda et al. (53) 136 Ibuprofen Placebo 24–72 h < 28 <1,000 25–50% + + + + + + ? Low
Amoozgar et al. (54) 51 Ibuprofen Placebo > 72 h > 33 >1,500 < 25% ? ? ? ? + + ? Intermediate
Maruyama et al. (55) 19 Indomethacin Placebo < 24 h UT < 28 <1,000 > 50% + + ? ? + + ? Intermediate
Sosenko et al. (56) 105 Ibuprofen Placebo 24–72 h < 28 <1,000 > 50% + + + + + + ? Low
Bagnoli et al. (57) 134 Ibuprofen Placebo > 72 h < 28 1,000–1,250 Unknown ? ? ? ? + + ? Intermediate
Kanmaz et al. (58) 46 Ibuprofen No treatment < 24 h UT < 28 <1,000 25–50% + + – + – + ? Intermediate
Ding et al. (59) 72 Ibuprofen Placebo Unknown 28–32 1,251–1,500 Unknown ? ? ? + + + ? Intermediate
Jannatdoust et al. (60) 70 Indomethacin No treatment < 24 h UT 28–32 Unknown 25–50% + + – ? ? + ? Intermediate
Kluckow et al. (61) 92 Indomethacin Placebo < 24 h T < 28 <1,000 25–50% + + + + + + – Low
Harkin et al. (62) 48 Acetaminophen Placebo < 24 h UT 28–32 1,000–1,250 < 25% + + + + + + ? Low
Clyman et al. (63) 202 Any No treatment > 72 h < 28 <1,000 25–50% + ? – ? + + – High
Juujarvi et al. (64) 44 Acetaminophen Placebo < 24 h UT 28–32 1,000–1,250 Unknown + + + + ? ? ? Intermediate
BW, birth weight; GA, gestational age; h, hour; n, number; NA, not available; PNA, postnatal age; any, indomethacin/ibuprofen/acetaminophen; T, targeted treatment, UT, untargeted
treatment; risk of bias numbers stand for (1) random sequence generation (selection bias); (2) allocation concealment (selection bias); (3) blinding of participants and personnel
(performance bias); (4) blinding of outcome assessment (detection bias); (5) incomplete outcome data (attrition bias); (6) selective reporting (reporting bias), and; (7) other bias.
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Risk ratio with 95% confidence interval. Number of studies and infants. RR < 1 favors treatment; RR > 1 favors placebo/no treatment. In bold the statistically significant differences. BW, birth weight; GA, gestational age; PNA, postnatal
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FIGURE 2 | Forest plots regarding the risk for intraventricular hemorrhage grade ≥ 3. BW, birth weight; GA, gestational age; PNA, postnatal age.
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The aim of this systematic review was to investigate whether
patient characteristics or study characteristics modulate the
beneficial or adverse effects of PDA treatment in preterm
infants. The main finding of this review was that pharmacologic
treatment of PDA is associated with a significantly reduced risk
of IVH grade ≥3 in extremely preterm infants (GA <28 weeks),
extremely low BW infants (BW <1,000 g), or when untargeted
treatment with indomethacin was started <24 h after birth.
Moreover, this review revealed no relevant significant differences
for the outcome measures NEC, BPD, mortality, sepsis, PVL, and
ROP between intervention and control groups in the subgroups
BW, GA, risk of bias, and rate of open-label treatment.
Our findings regarding the reduced risk of IVH grade ≥3 is
in line with a previous review comprising 2,588 newborns <37
weeks’ gestation, which showed that untargeted administration
of indomethacin is associated with a decreased risk of IVH
(65). In our meta-analysis a total of 2,937 preterm infants
were assessed for IVH grade ≥3 and stratified by BW, GA,
and PNA. Out of the infants allocated to the treatment group
10% had IVH grade ≥3 compared to 13% of the infants in
the placebo/no treatment group. Dividing the included studies
who treated the infants <24 h after birth into untargeted
treatment or targeted treatment, we found only reduction
of severe IVH in the former group if indomethacin was
used. The hypothesis is that this reduction of severe IVH
is probably not a direct effect of ductal closure itself and
therefore limiting cerebral perfusion disturbances, but mediated
by prevention of hyperperfusion by a direct drug-induced
cerebrovascular vasoconstriction (see Figure 3). This effect
has been demonstrated for indomethacin and might prevent
the cerebral hypoperfusion-hyperperfusion sequence, which is
considered to be an important pathophysiological mechanism
associated with IVH (66–69).
Subdividing the studies according to which drug was used,
we found no significant differences in the incidences of NEC,
BPD, ROP or mortality, which is in line with recently published
papers (11, 14). In contrast to our meta-analysis, these papers
used any grade of IVH instead of severe IVH as outcome
parameter and observed no significant differences in any of
the used drugs vs. placebo/no treatment. Our review selected
studies published between 1985 and 2019, whereas currently, as
opposed to the previous century, most preterm infants will have
received corticosteroids antenatally and surfactants postnatally,
if required. We know that this approach reduces the risk of an
IVH (70). Including only those studies published in the last 25
years, the significant reduction of severe IVH is still observed in
the youngest, smallest and untargeted treated infants.
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Although untargeted treatment constitutes the only
convincing evidence for active closure of PDA, it is currently
seldom provided (1). It might, however, be argued that any
evidence-based reduction in the risk of IVH grade ≥3 is
beneficial to the infant, but sufficient evidence is lacking. In a
2015 meta-analysis about neurodevelopmental impairment after
a severe IVH, only observational cohort studies were identified
and on the whole the risk of bias was high (71). Moreover, there
is also little evidence of improved long-term developmental
outcome and mortality after prophylactic treatment (44, 45, 65).
In addition, we stratified by rate of open-label treatment,
something that to our knowledge has not been done before.
The median rate of the open-label treatment in the studies
was 44.5% (calculated from 38 out of 47 studies). Since we
reviewed the raw data in our meta-analysis to determine the
morbidity and mortality of the different subgroups, we could
not analyze whether the original studies performed intention
to treat or per protocol analysis. We hypothesized that the
potential effects of active treatment of a PDAwould be attenuated
in RCTs with a high proportion of open label treatment in
the control/placebo arm. However, this was not observed.
Failure of DA closure and the need for surgical ligation were
significantly lower in the treatment group independent of
the rate of open-label treatment. To our surprise, however,
this subgroup analysis, which stratified the studies according
to a high rate vs. a lower rate of open-label treatment in
the control group, showed no difference in morbidity and
mortality. We found no significant reduction of major clinical
outcomes, not even in the subgroup of RCTs with low open-
label treatment rates in the no treatment group of patients. This
raises the question whether a PDA should be considered as
an epiphenomenon as was suggested by recent cohort studies
using restrictive treatment policies (72, 73). This should, however,
be supported or refuted by well-powered high-quality RCTs
targeting the high-risk population (<28 weeks’ GA and/or BW
<1,000 g) with low-rate open-label treatment of the placebo/no
treatment group.
Limitations
The first limitation of this meta-analysis are the missing data
in the RCTs. Unfortunately, even though we tried to reduce
selection bias by contacting the corresponding authors, not all
missing data could be retrieved. As a consequence, we could not
include all studies in our subgroup stratification.
Secondly, a meta-analysis has to deal with heterogeneity
of the included RCTs. The high statistical heterogeneity in
this meta-analysis is comparable with a previously published
meta-analyses (74). Heterogeneity leads to lower quality of
evidence (5, 75). In an attempt to reduce clinical heterogeneity,
we stratified the results in several subgroups and subdivided
treatment started <24 h after birth in untargeted treatment
and targeted treatment. Moreover, the definitions of outcome
measures in the included RCTs in a meta-analysis vary.
In the current meta-analysis, the outcomes BPD and NEC
were not uniformly defined in the selected studies. The
possible reason is the large spread in publication years;
criteria for short-term morbidities have changed over the
years. Nevertheless, neither the overall meta-analyses nor the
subgroup analyses of the different BPD definitions revealed any
differences. The heterogeneity of studies analyzing NEC was low.
Unfortunately, subgroup analyses could not be performed for
the outcome measures pneumothorax, pulmonary hemorrhage,
pulmonary hypertension, gastro-intestinal bleeding, SIP, and
oliguria, because of the scarcity of available data. Last, another
important factor that could be a major factor contributing to
heterogeneity is the classification of hemodynamic significance
of the PDA. Zonnenberg et al. showed that there is substantial
variability in the definition of a significant PDA in clinical
trials (9). In the 47 included RCTs the used definition of
a PDA varied much, ranging from clinical, radiographic and
echocardiographic parameters.
Future research is required with unambiguously definitions of
outcome measures and larger groups of preterm infants. There is
a need for well-powered high-quality RCTs with low-rate open-
label treatment of the placebo/no treatment group. In addition,
more research is needed to investigate which mechanisms might
be responsible for the reduction of IVH grade≥3 in the youngest,
the smallest, or in the preterm infants that are treated untargeted
with indomethacin within the first 24 h of life.
Conclusions
In this systematic review, in which we investigated the
modulating effects of patient characteristics and study
characteristics by performing subgroup meta-analyses, the
degree of heterogeneity among the included studies and
variability in study quality is high. Therefore, the quality of
evidence following GRADE assessment is low. Pharmacological
treatment of a PDA in extremely preterm infants with either
a GA <28 weeks, a BW <1,000 g, or if untargeted treatment
with indomethacin is given <24 h PNA is associated with
a significantly lower risk of developing IVH grade ≥3. We
found no differences in the incidence of other morbidities or in
mortality when we stratified the subgroups by BW, GA, and PNA
at start of treatment. Important data on long-term consequences
of neurodevelopmental impairment are lacking for these studies.
More high-quality and low-rate open-label treatment studies are
needed to unravel the effects of pharmacological PDA treatment
on short-term and long-term morbidity and to elucidate
underlying pathophysiologic mechanisms.
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